We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Analysis of Placental Cell Free DNA and RNA Predicts Gestational Complications

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Image: Schematic view of the placenta (Photo courtesy of Wikimedia Commons)
Image: Schematic view of the placenta (Photo courtesy of Wikimedia Commons)
A recent paper revealed that circulating cell-free nucleic acids (DNA and RNA) shed from the placenta into the mother's blood during the first trimester of pregnancy could be used to predict potentially serious complications such as ischemic placental disease and gestational diabetes.

Although analysis of maternal plasma cell-free content has been employed for screening of genetic abnormalities within a pregnancy, limited attention has been paid to its use for the detection of adverse pregnancy outcomes based on placental function.

In this light, investigators at the University of California, Los Angeles (USA) analyzed the cell-free DNA and RNA content of 102 maternal and 25 cord plasma samples obtained from a group of pregnant women between February 2017 and January 2019. A total of 160 of the participants gave birth by the end of the study.

Results revealed that during the first trimester, placenta-specific DNA increased prior to the subsequent development of gestational diabetes with no change in patients with pre-eclampsia while decreasing with maternal obesity. Moreover, using cell-free RNA sequencing, adverse pregnancy outcomes revealed 71 differentially expressed genes early in pregnancy. In particular, the investigators noted upregulation of the S100A8, MS4A3, and MMP8 genes that had been already associated with adverse pregnancy outcomes but also the upregulation of BCL2L15 and the downregulation of ALPL that had never been associated with adverse pregnancy outcomes.

These results enabled the investigators to construct a classifier with a positive predictive ability of 0.91 for adverse pregnancy outcomes, 0.86 for pre-eclampsia alone, and 0.64 for gestational diabetes.

"Our research points to a promising approach that could improve outcomes for mothers and their babies using existing technologies," said senior author Dr. Sherin Devaskar, professor of pediatrics at the University of California, Los Angeles. "If confirmed in larger studies, cell-free DNA blood tests may help identify issues in the placenta as an indicator of a healthy mother and fetus. The novelty of this research is being able to break down a mother's DNA and be able to hone in on the health of the placenta - something that researchers have never been able to do before. This research warrants application of automated methodologies in multi-center trials to improve future testing and screening for all women."

The study was published in the October 13, 2020, online edition of the journal Epigenetics.

Related Links:
University of California, Los Angeles

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.